首页 > 最新文献

Sarcoma最新文献

英文 中文
Testicular, Spermatic Cord, and Scrotal Soft Tissue Sarcomas: Treatment Outcomes and Patterns of Failure. 睾丸、精索和阴囊软组织肉瘤:治疗结果和失败模式。
Q2 Medicine Pub Date : 2021-03-05 eCollection Date: 2021-01-01 DOI: 10.1155/2021/8824301
Varun K Chowdhry, John M Kane, Katy Wang, Daniel Joyce, Anne Grand'Maison, Gary N Mann

Introduction: Paratesticular sarcomas are defined as tumors that arise within the scrotum and include the subsites of epididymis, spermatic cord, and tunica vaginalis and represent the most common type of GU sarcoma. The mainstay of treatment is often surgical resection, combined with histology specific chemotherapy and radiotherapy. Due to the rare nature of the disease, there are limited data to guide management. We present our single-institution retrospective experience regarding the management and treatment of paratesticular sarcomas.

Materials and methods: We queried our oncology registry database for patients treated for testicular, spermatic cord, and scrotal soft tissue sarcomas between 1971 and 2017. Patients in this series had pathological confirmation of a sarcoma diagnosis by a sarcoma-specialized pathologist. Only patients with localized disease were included in this analysis with the exception of patients with a diagnosis of rhabdomyosarcoma where patients with both localized and metastatic disease were included on this study.

Results: A total of 34 patients were included in this retrospective analysis. The median was 24 (range, 5-78), and the median tumor size was 6.25 cm. Twenty-six patients had localized disease (76.6%) at the time of diagnosis. A predominance of patients had tumors involving the spermatic cord (45.5%), and the most common histology was rhabdomyosarcoma (35.3%), leiomyosarcoma (26.5%), and well-differentiated liposarcoma (23.5%). The median follow-up was 71.0 months (range, 2.5-534.4 months). A total of 7 patients experienced an isolated local failure (20.6%), four patients developed distant metastatic disease (11.8%), and one patient (2.9%) with synovial sarcoma of the spermatic cord experienced a regional recurrence. The median progression-free survival (PFS) was 99.6 months, 95% CI (45.8-534.3 months), with a three-year PFS rate of 71%, 95% CI (53%-83%), and a 5-year PFS rate of 64% (range, 46%-78%). We did not find any statistically significant associations based on surgery type (p=0.15), the use of chemotherapy, (p=0.36), or final margin status (p=0.21). Two patients who were treated with preoperative radiotherapy had significant wound healing complication with chronic sinus tracts, though these patients did not experience a local recurrence.

Conclusions: We provide a characterization of the natural history and treatment patterns of paratesticular sarcomas. While effective at reducing a local recurrence, preoperative radiotherapy was associated with significant toxicity. As a result, we prefer the use of postoperative radiotherapy in patients as clinically indicated. We did not find any specific treatment patterns associated with an improvement in clinical outcomes.

导言:睾丸旁肉瘤是指发生在阴囊内的肿瘤,包括附睾、精索和阴道韧带,是最常见的生殖器肉瘤类型。治疗的主要方法通常是手术切除,并结合组织学特异性化疗和放疗。由于这种疾病非常罕见,因此指导治疗的数据非常有限。我们将介绍单个机构在睾丸旁肉瘤管理和治疗方面的回顾性经验:我们在肿瘤登记数据库中查询了1971年至2017年间接受睾丸、精索和阴囊软组织肉瘤治疗的患者。该系列患者均由肉瘤专科病理学家进行病理确诊。除诊断为横纹肌肉瘤的患者外,只有患有局部疾病的患者才被纳入本分析中,而患有局部疾病和转移性疾病的患者均被纳入本研究中:本次回顾性分析共纳入34名患者。中位数为 24(5-78),中位肿瘤大小为 6.25 厘米。诊断时,26 名患者(76.6%)患有局部疾病。大多数患者的肿瘤累及精索(45.5%),最常见的组织学类型为横纹肌肉瘤(35.3%)、亮肌肉瘤(26.5%)和分化良好的脂肪肉瘤(23.5%)。中位随访时间为 71.0 个月(2.5-534.4 个月)。共有7名患者(20.6%)出现局部治疗失败,4名患者(11.8%)出现远处转移,1名精索滑膜肉瘤患者(2.9%)出现区域性复发。中位无进展生存期(PFS)为99.6个月,95% CI(45.8-534.3个月),3年PFS率为71%,95% CI(53%-83%),5年PFS率为64%(46%-78%)。我们没有发现与手术类型(P=0.15)、化疗使用(P=0.36)或最终边缘状态(P=0.21)有任何统计学意义的关联。两名接受术前放疗的患者出现了明显的伤口愈合并发症,并伴有慢性窦道,但这些患者并未出现局部复发:我们对睾丸旁肉瘤的自然史和治疗模式进行了描述。术前放疗虽然能有效减少局部复发,但却有明显的毒性。因此,我们倾向于在有临床指征的患者中使用术后放疗。我们没有发现任何特定的治疗模式能改善临床疗效。
{"title":"Testicular, Spermatic Cord, and Scrotal Soft Tissue Sarcomas: Treatment Outcomes and Patterns of Failure.","authors":"Varun K Chowdhry, John M Kane, Katy Wang, Daniel Joyce, Anne Grand'Maison, Gary N Mann","doi":"10.1155/2021/8824301","DOIUrl":"10.1155/2021/8824301","url":null,"abstract":"<p><strong>Introduction: </strong>Paratesticular sarcomas are defined as tumors that arise within the scrotum and include the subsites of epididymis, spermatic cord, and tunica vaginalis and represent the most common type of GU sarcoma. The mainstay of treatment is often surgical resection, combined with histology specific chemotherapy and radiotherapy. Due to the rare nature of the disease, there are limited data to guide management. We present our single-institution retrospective experience regarding the management and treatment of paratesticular sarcomas.</p><p><strong>Materials and methods: </strong>We queried our oncology registry database for patients treated for testicular, spermatic cord, and scrotal soft tissue sarcomas between 1971 and 2017. Patients in this series had pathological confirmation of a sarcoma diagnosis by a sarcoma-specialized pathologist. Only patients with localized disease were included in this analysis with the exception of patients with a diagnosis of rhabdomyosarcoma where patients with both localized and metastatic disease were included on this study.</p><p><strong>Results: </strong>A total of 34 patients were included in this retrospective analysis. The median was 24 (range, 5-78), and the median tumor size was 6.25 cm. Twenty-six patients had localized disease (76.6%) at the time of diagnosis. A predominance of patients had tumors involving the spermatic cord (45.5%), and the most common histology was rhabdomyosarcoma (35.3%), leiomyosarcoma (26.5%), and well-differentiated liposarcoma (23.5%). The median follow-up was 71.0 months (range, 2.5-534.4 months). A total of 7 patients experienced an isolated local failure (20.6%), four patients developed distant metastatic disease (11.8%), and one patient (2.9%) with synovial sarcoma of the spermatic cord experienced a regional recurrence. The median progression-free survival (PFS) was 99.6 months, 95% CI (45.8-534.3 months), with a three-year PFS rate of 71%, 95% CI (53%-83%), and a 5-year PFS rate of 64% (range, 46%-78%). We did not find any statistically significant associations based on surgery type (<i>p</i>=0.15), the use of chemotherapy, (<i>p</i>=0.36), or final margin status (<i>p</i>=0.21). Two patients who were treated with preoperative radiotherapy had significant wound healing complication with chronic sinus tracts, though these patients did not experience a local recurrence.</p><p><strong>Conclusions: </strong>We provide a characterization of the natural history and treatment patterns of paratesticular sarcomas. While effective at reducing a local recurrence, preoperative radiotherapy was associated with significant toxicity. As a result, we prefer the use of postoperative radiotherapy in patients as clinically indicated. We did not find any specific treatment patterns associated with an improvement in clinical outcomes.</p>","PeriodicalId":21431,"journal":{"name":"Sarcoma","volume":"2021 ","pages":"8824301"},"PeriodicalIF":0.0,"publicationDate":"2021-03-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7954631/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"25500530","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Prognostic and Therapeutic Utility of Variably Expressed Cell Surface Receptors in Osteosarcoma. 骨肉瘤中变表达细胞表面受体的预后和治疗价值。
Q2 Medicine Pub Date : 2021-02-02 eCollection Date: 2021-01-01 DOI: 10.1155/2021/8324348
Yoav Zvi, Elif Ugur, Brian Batko, Jonathan Gill, Michael Roth, Richard Gorlick, David Hall, Janet Tingling, Donald A Barkauskas, Jinghang Zhang, Rui Yang, Bang H Hoang, David S Geller

Background: Six cell surface receptors, human epidermal growth factor receptor-2 (Her-2), platelet-derived growth factor receptor-β (PDGFR-β), insulin-like growth factor-1 receptor (IGF-1R), insulin receptor (IR), c-Met, and vascular endothelial growth factor receptor-3 (VEGFR-3), previously demonstrated variable expression across varying patient-derived and standard osteosarcoma (OS) cell lines. The current study sought to validate previous expression patterns and evaluate whether these receptors offer prognostic and/or therapeutic value.

Methods: Patient-derived OS cell lines (n = 52) were labeled with antibodies to Her-2, PDGFR-β, IGF-1R, IR, c-Met, and VEGFR-3. Expression was characterized using flow cytometry. The difference in geometric mean fluorescent intensity (geoMFIdiff = geoMFIpositive - geoMFInegative) was calculated for each receptor across all cell lines. Receptor expression was categorized as low (Q1), intermediate (Q2, Q3), or high (Q4). The event-free survival (EFS) and overall survival for the six cell surface receptors were estimated by the Kaplan-Meier method. Differences in hazard for EFS event and overall survival event for patients in each of the three expression levels in each of the six cell surface receptors were assessed using the log-rank test.

Results: All 6 receptors were variably expressed in the majority of cell lines. IR and PDGFR-β expressions were found to be significant predictors for EFS amongst patients with nonmetastatic disease (p=0.02 and 0.01, respectively). The hazard ratio for EFS was significantly higher between high IR and intermediate IR expression (HR = 2.66, p=0.02), as well as between high PDGFR-β and intermediate PDGFR-β expression (HR = 5.68, p=0.002). Her-2, c-Met, IGF-1R, and VEGFR-3 were not found to be significant predictors for either EFS or overall survival.

Conclusion: The six cell surface receptors demonstrated variable expression across the majority of patient-derived OS cell lines tested. Limited prognostic value was offered by IR and PDGFR-β expression within nonmetastatic patients. The remaining receptors do not provide clear prognostic utility. Nevertheless, their consistent, albeit variable, surface expression across a large panel of patient-derived OS cell lines maintains their potential use as future therapeutic targets.

背景:六种细胞表面受体,人表皮生长因子受体-2 (Her-2),血小板来源的生长因子受体-β (PDGFR-β),胰岛素样生长因子-1受体(IGF-1R),胰岛素受体(IR), c-Met和血管内皮生长因子受体-3 (VEGFR-3),先前在不同的患者来源和标准骨肉瘤(OS)细胞系中表现出不同的表达。目前的研究旨在验证先前的表达模式,并评估这些受体是否具有预后和/或治疗价值。方法:用Her-2、PDGFR-β、IGF-1R、IR、c-Met和VEGFR-3抗体标记患者来源的OS细胞系(n = 52)。流式细胞术检测表达。计算了所有细胞系中每种受体的几何平均荧光强度(geoMFIdiff = geoMFIpositive - geoMFInegative)的差异。受体表达分为低(Q1)、中(Q2、Q3)和高(Q4)。用Kaplan-Meier法估计6种细胞表面受体的无事件生存期(EFS)和总生存期。使用log-rank检验评估六种细胞表面受体的三种表达水平下患者EFS事件和总生存事件的危险差异。结果:6种受体在大多数细胞系中均有表达。发现IR和PDGFR-β表达是非转移性疾病患者EFS的重要预测因子(p分别=0.02和0.01)。高IR和中等IR表达之间以及高PDGFR-β和中等PDGFR-β表达之间的风险比(HR = 2.66, p=0.02)显著高于EFS (HR = 5.68, p=0.002)。Her-2、c-Met、IGF-1R和VEGFR-3不是EFS或总生存期的重要预测因子。结论:六种细胞表面受体在大多数患者来源的OS细胞系中表现出不同的表达。在非转移性患者中,IR和PDGFR-β表达提供的预后价值有限。其余受体没有提供明确的预后效用。尽管如此,它们在大量患者来源的OS细胞系中的一致(尽管是可变的)表面表达保持了它们作为未来治疗靶点的潜在用途。
{"title":"Prognostic and Therapeutic Utility of Variably Expressed Cell Surface Receptors in Osteosarcoma.","authors":"Yoav Zvi,&nbsp;Elif Ugur,&nbsp;Brian Batko,&nbsp;Jonathan Gill,&nbsp;Michael Roth,&nbsp;Richard Gorlick,&nbsp;David Hall,&nbsp;Janet Tingling,&nbsp;Donald A Barkauskas,&nbsp;Jinghang Zhang,&nbsp;Rui Yang,&nbsp;Bang H Hoang,&nbsp;David S Geller","doi":"10.1155/2021/8324348","DOIUrl":"https://doi.org/10.1155/2021/8324348","url":null,"abstract":"<p><strong>Background: </strong>Six cell surface receptors, human epidermal growth factor receptor-2 (Her-2), platelet-derived growth factor receptor-<i>β</i> (PDGFR-<i>β</i>), insulin-like growth factor-1 receptor (IGF-1R), insulin receptor (IR), c-Met, and vascular endothelial growth factor receptor-3 (VEGFR-3), previously demonstrated variable expression across varying patient-derived and standard osteosarcoma (OS) cell lines. The current study sought to validate previous expression patterns and evaluate whether these receptors offer prognostic and/or therapeutic value.</p><p><strong>Methods: </strong>Patient-derived OS cell lines (<i>n</i> = 52) were labeled with antibodies to Her-2, PDGFR-<i>β</i>, IGF-1R, IR, c-Met, and VEGFR-3. Expression was characterized using flow cytometry. The difference in geometric mean fluorescent intensity (geoMFI<sub>diff</sub> = geoMFI<sub>positive</sub> - geoMFI<sub>negative</sub>) was calculated for each receptor across all cell lines. Receptor expression was categorized as low (Q1), intermediate (Q2, Q3), or high (Q4). The event-free survival (EFS) and overall survival for the six cell surface receptors were estimated by the Kaplan-Meier method. Differences in hazard for EFS event and overall survival event for patients in each of the three expression levels in each of the six cell surface receptors were assessed using the log-rank test.</p><p><strong>Results: </strong>All 6 receptors were variably expressed in the majority of cell lines. IR and PDGFR-<i>β</i> expressions were found to be significant predictors for EFS amongst patients with nonmetastatic disease (<i>p</i>=0.02 and 0.01, respectively). The hazard ratio for EFS was significantly higher between high IR and intermediate IR expression (HR = 2.66, <i>p</i>=0.02), as well as between high PDGFR-<i>β</i> and intermediate PDGFR-<i>β</i> expression (HR = 5.68, <i>p</i>=0.002). Her-2, c-Met, IGF-1R, and VEGFR-3 were not found to be significant predictors for either EFS or overall survival.</p><p><strong>Conclusion: </strong>The six cell surface receptors demonstrated variable expression across the majority of patient-derived OS cell lines tested. Limited prognostic value was offered by IR and PDGFR-<i>β</i> expression within nonmetastatic patients. The remaining receptors do not provide clear prognostic utility. Nevertheless, their consistent, albeit variable, surface expression across a large panel of patient-derived OS cell lines maintains their potential use as future therapeutic targets.</p>","PeriodicalId":21431,"journal":{"name":"Sarcoma","volume":"2021 ","pages":"8324348"},"PeriodicalIF":0.0,"publicationDate":"2021-02-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7872755/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"25387250","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 7
Corrigendum to "Clinical Presentation, Natural History, and Therapeutic Approach in Patients with Solitary Fibrous Tumor: A Retrospective Analysis". 对“孤立性纤维性肿瘤患者的临床表现、自然病史和治疗方法:回顾性分析”的更正。
Q2 Medicine Pub Date : 2021-01-29 eCollection Date: 2021-01-01 DOI: 10.1155/2021/4653987
P Schöffski, I Timmermans, D Hompes, M Stas, Veerle Boecxstaens, F Sinnaeve, P De Leyn, W Coosemans, D Van Raemdonck, E Hauben, R Sciot, P Clement, O Bechter, B Beuselinck, F J S H Woei-A-Jin, H Dumez, P Nafteux, T Wessels

[This corrects the article DOI: 10.1155/2020/1385978.].

[这更正了文章DOI: 10.1155/2020/1385978.]。
{"title":"Corrigendum to \"Clinical Presentation, Natural History, and Therapeutic Approach in Patients with Solitary Fibrous Tumor: A Retrospective Analysis\".","authors":"P Schöffski,&nbsp;I Timmermans,&nbsp;D Hompes,&nbsp;M Stas,&nbsp;Veerle Boecxstaens,&nbsp;F Sinnaeve,&nbsp;P De Leyn,&nbsp;W Coosemans,&nbsp;D Van Raemdonck,&nbsp;E Hauben,&nbsp;R Sciot,&nbsp;P Clement,&nbsp;O Bechter,&nbsp;B Beuselinck,&nbsp;F J S H Woei-A-Jin,&nbsp;H Dumez,&nbsp;P Nafteux,&nbsp;T Wessels","doi":"10.1155/2021/4653987","DOIUrl":"https://doi.org/10.1155/2021/4653987","url":null,"abstract":"<p><p>[This corrects the article DOI: 10.1155/2020/1385978.].</p>","PeriodicalId":21431,"journal":{"name":"Sarcoma","volume":"2021 ","pages":"4653987"},"PeriodicalIF":0.0,"publicationDate":"2021-01-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7884164/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"25402253","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Sarcoma of the Breast: Clinical Characteristics and Outcomes of 991 Patients from the National Cancer Database. 乳腺肉瘤:来自国家癌症数据库的991例患者的临床特征和结果
Q2 Medicine Pub Date : 2021-01-21 eCollection Date: 2021-01-01 DOI: 10.1155/2021/8828158
Jin Sun Lee, Kevin Yoon, Mykola Onyshchenko

Background: Sarcoma of the breast is a rare malignancy with heterogeneous histology. Angiosarcoma, including secondary angiosarcoma from previous radiation, is the most common type of sarcoma of the breast. Other types of sarcomas of the breast have limited clinical and survival information.

Methods: We obtained clinicopathological data and survival outcomes from the patients with sarcoma of the breast, excluding angiosarcoma, that were registered in the National Cancer Database (NCDB) from 2004 to 2016. The treatment patterns and prognostic factors were analyzed.

Results: A total of 991 patients had sarcoma of the breast other than angiosarcoma. The most common histology was spindle cell sarcoma (13.4%), followed by leiomyosarcoma (11.7%) and giant cell sarcoma (10.1%). Surgical resection was performed in 894 out of 991 patients (90.2%), including R0 resection achieved in 781 (87.4%). The patients who received surgery showed better survival than the patients without surgery regardless of radiation therapy. When radiation was added to the surgical management, the OS (overall survival) benefit was marginally significant (hazard ratio 1.30 (CI 1.01-1.67), p=0.044). Adding chemotherapy did not improve OS.

Conclusions: Surgical resection seems to be the most important treatment modality in sarcoma of the breast from the analysis of a large database. Radiation therapy added a minor survival benefit to the patients who received surgical resection. Systemic chemotherapy did not play a clear role in sarcoma of the breast.

背景:乳腺肉瘤是一种罕见的组织学异质性恶性肿瘤。血管肉瘤,包括继发性血管肉瘤,是乳房最常见的肉瘤类型。其他类型的乳腺肉瘤的临床和生存信息有限。方法:我们获得2004年至2016年在国家癌症数据库(NCDB)中登记的乳腺肉瘤(不包括血管肉瘤)患者的临床病理数据和生存结果。分析治疗方式及影响预后的因素。结果:991例患者除血管肉瘤外发生乳腺肉瘤。最常见的组织学为梭形细胞肉瘤(13.4%),其次为平滑肌肉瘤(11.7%)和巨细胞肉瘤(10.1%)。991例患者中有894例(90.2%)行手术切除,其中781例(87.4%)行R0切除。无论放射治疗如何,接受手术的患者比未接受手术的患者生存率更高。当在手术治疗中加入放射治疗时,总生存期(OS)的获益略有显著(风险比1.30 (CI 1.01-1.67), p=0.044)。增加化疗没有改善OS。结论:从一个大型数据库的分析来看,手术切除似乎是乳房肉瘤最重要的治疗方式。放射治疗为接受手术切除的患者增加了少量的生存益处。全身化疗在乳腺肉瘤中没有明确的作用。
{"title":"Sarcoma of the Breast: Clinical Characteristics and Outcomes of 991 Patients from the National Cancer Database.","authors":"Jin Sun Lee,&nbsp;Kevin Yoon,&nbsp;Mykola Onyshchenko","doi":"10.1155/2021/8828158","DOIUrl":"https://doi.org/10.1155/2021/8828158","url":null,"abstract":"<p><strong>Background: </strong>Sarcoma of the breast is a rare malignancy with heterogeneous histology. Angiosarcoma, including secondary angiosarcoma from previous radiation, is the most common type of sarcoma of the breast. Other types of sarcomas of the breast have limited clinical and survival information.</p><p><strong>Methods: </strong>We obtained clinicopathological data and survival outcomes from the patients with sarcoma of the breast, excluding angiosarcoma, that were registered in the National Cancer Database (NCDB) from 2004 to 2016. The treatment patterns and prognostic factors were analyzed.</p><p><strong>Results: </strong>A total of 991 patients had sarcoma of the breast other than angiosarcoma. The most common histology was spindle cell sarcoma (13.4%), followed by leiomyosarcoma (11.7%) and giant cell sarcoma (10.1%). Surgical resection was performed in 894 out of 991 patients (90.2%), including R0 resection achieved in 781 (87.4%). The patients who received surgery showed better survival than the patients without surgery regardless of radiation therapy. When radiation was added to the surgical management, the OS (overall survival) benefit was marginally significant (hazard ratio 1.30 (CI 1.01-1.67), <i>p</i>=0.044). Adding chemotherapy did not improve OS.</p><p><strong>Conclusions: </strong>Surgical resection seems to be the most important treatment modality in sarcoma of the breast from the analysis of a large database. Radiation therapy added a minor survival benefit to the patients who received surgical resection. Systemic chemotherapy did not play a clear role in sarcoma of the breast.</p>","PeriodicalId":21431,"journal":{"name":"Sarcoma","volume":"2021 ","pages":"8828158"},"PeriodicalIF":0.0,"publicationDate":"2021-01-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7843167/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"25333180","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 6
Sarcoma 肉瘤
Q2 Medicine Pub Date : 2021-01-01 DOI: 10.1007/978-981-15-9414-4
F. Traub, D. Andreou, M. Niethard, C. Tiedke, M. Werner, P. Tunn
{"title":"Sarcoma","authors":"F. Traub, D. Andreou, M. Niethard, C. Tiedke, M. Werner, P. Tunn","doi":"10.1007/978-981-15-9414-4","DOIUrl":"https://doi.org/10.1007/978-981-15-9414-4","url":null,"abstract":"","PeriodicalId":21431,"journal":{"name":"Sarcoma","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1007/978-981-15-9414-4","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"51108782","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Clear Cell Chondrosarcoma: Clinical Characteristics and Outcomes in 15 Patients 透明细胞软骨肉瘤:15例患者的临床特征和结果
Q2 Medicine Pub Date : 2020-12-29 DOI: 10.1155/2020/2386191
J. Flint, A. Conley, M. L. Rubin, Lei Feng, P. Lin, Bryan S Moon, J. Bird, R. Satcher, Valerae O. Lewis
Background. Clear cell chondrosarcoma (CCC) represents less than 6% of all chondrosarcomas, and thus, our understanding of this rare entity is limited. Analyzing clinical characteristics and treatment patterns, thus increasing our knowledge, may improve treatment strategy. We review our institutional experience with 15 patients, including one case with dedifferentiation. Methods. A retrospective review was conducted in CCC patients treated at our institution from 1996 to 2015, with at least 2-year follow-up. Descriptive statistics and Kaplan–Meier survival analyses were performed. Results. Of 19 patients identified, 15 patients had at least 2-year follow-up and were included. The median age at diagnosis was 43 years. 80% were male. The most common presenting signs were pain (12 patients; 80%) and fracture (2 patients; 13.3%). The most common site was proximal femur (8 patients; 53%). All patients had MSTS Stage I disease. Primary treatment included wide resection in 10 patients (67%) and intralesional or marginal resection in 5 patients (33%). Three patients died of disease during the study period, 1 with dedifferentiation of recurrent CCC. The median time to death from disease was 15.3 years (95% CI: (14.2; NA)). The median time to either recurrence or death was 7.73 years for patients who had intralesional/marginal resection and 16.44 years for patients with wide resection (HR (wide vs. intralesional/marginal) = 0.21, 95% CI: (0.04; 1.18), p = 0.053 ). The median time to recurrence or death was significantly shorter for patients not initially treated at a sarcoma center ( p = 0.01 ). Conclusions. CCC is a rare entity, and our understanding of it is still evolving. We observed a higher recurrence rate for intralesional or marginal resection, and wide resection alone remains the mainstay of treatment. Better outcomes were observed in patients initially treated by trained musculoskeletal oncologists. Due to the propensity of CCC to recur decades after initial resection, lifelong surveillance is recommended.
背景透明细胞软骨肉瘤(CCC)不到所有软骨肉瘤的6%,因此,我们对这种罕见实体的了解有限。分析临床特征和治疗模式,从而增加我们的知识,可能会改进治疗策略。我们回顾了我们对15名患者的机构经验,其中包括一例去分化患者。方法。对1996年至2015年在我院接受治疗的CCC患者进行了回顾性审查,并进行了至少2年的随访。进行描述性统计和Kaplan-Meier生存率分析。后果在确定的19名患者中,有15名患者进行了至少2年的随访,并纳入其中。诊断时的中位年龄为43岁。80%为男性。最常见的症状是疼痛(12例;80%)和骨折(2例;13.3%)。最常见的部位是股骨近端(8例;53%)。所有患者均患有MSTS I期疾病。主要治疗包括10例患者(67%)的广泛切除和5例患者(33%)的病灶内或边缘切除。3名患者在研究期间死于疾病,1名患者复发性CCC去分化。死于疾病的中位时间为15.3年(95%置信区间:(14.2;NA))。病灶内/边缘切除的患者复发或死亡的中位时间为7.73年,广泛切除的患者为16.44年(HR(广泛与病灶内/边界) = 0.21,95%可信区间:(0.04;1.18),p=0.053)。对于最初未在肉瘤中心接受治疗的患者,复发或死亡的中位时间明显更短(p=0.01)。结论。CCC是一个罕见的实体,我们对它的理解仍在不断发展。我们观察到病灶内或边缘切除术的复发率更高,单独的广泛切除仍然是主要的治疗方法。在最初由受过训练的肌肉骨骼肿瘤学家治疗的患者中观察到了更好的结果。由于CCC在初次切除几十年后复发的倾向,建议终身监测。
{"title":"Clear Cell Chondrosarcoma: Clinical Characteristics and Outcomes in 15 Patients","authors":"J. Flint, A. Conley, M. L. Rubin, Lei Feng, P. Lin, Bryan S Moon, J. Bird, R. Satcher, Valerae O. Lewis","doi":"10.1155/2020/2386191","DOIUrl":"https://doi.org/10.1155/2020/2386191","url":null,"abstract":"Background. Clear cell chondrosarcoma (CCC) represents less than 6% of all chondrosarcomas, and thus, our understanding of this rare entity is limited. Analyzing clinical characteristics and treatment patterns, thus increasing our knowledge, may improve treatment strategy. We review our institutional experience with 15 patients, including one case with dedifferentiation. Methods. A retrospective review was conducted in CCC patients treated at our institution from 1996 to 2015, with at least 2-year follow-up. Descriptive statistics and Kaplan–Meier survival analyses were performed. Results. Of 19 patients identified, 15 patients had at least 2-year follow-up and were included. The median age at diagnosis was 43 years. 80% were male. The most common presenting signs were pain (12 patients; 80%) and fracture (2 patients; 13.3%). The most common site was proximal femur (8 patients; 53%). All patients had MSTS Stage I disease. Primary treatment included wide resection in 10 patients (67%) and intralesional or marginal resection in 5 patients (33%). Three patients died of disease during the study period, 1 with dedifferentiation of recurrent CCC. The median time to death from disease was 15.3 years (95% CI: (14.2; NA)). The median time to either recurrence or death was 7.73 years for patients who had intralesional/marginal resection and 16.44 years for patients with wide resection (HR (wide vs. intralesional/marginal) = 0.21, 95% CI: (0.04; 1.18), \u0000 \u0000 p\u0000 =\u0000 0.053\u0000 \u0000 ). The median time to recurrence or death was significantly shorter for patients not initially treated at a sarcoma center (\u0000 \u0000 p\u0000 =\u0000 0.01\u0000 \u0000 ). Conclusions. CCC is a rare entity, and our understanding of it is still evolving. We observed a higher recurrence rate for intralesional or marginal resection, and wide resection alone remains the mainstay of treatment. Better outcomes were observed in patients initially treated by trained musculoskeletal oncologists. Due to the propensity of CCC to recur decades after initial resection, lifelong surveillance is recommended.","PeriodicalId":21431,"journal":{"name":"Sarcoma","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2020-12-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46686545","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Soft Tissue Tumour Pathology 软组织肿瘤病理学
Q2 Medicine Pub Date : 2020-12-10 DOI: 10.1007/978-981-15-9414-4_7
Vanessa Tran, J. Slavin
{"title":"Soft Tissue Tumour Pathology","authors":"Vanessa Tran, J. Slavin","doi":"10.1007/978-981-15-9414-4_7","DOIUrl":"https://doi.org/10.1007/978-981-15-9414-4_7","url":null,"abstract":"","PeriodicalId":21431,"journal":{"name":"Sarcoma","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2020-12-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48925501","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Bone Tumour Pathology 骨瘤病理学
Q2 Medicine Pub Date : 2020-12-10 DOI: 10.1007/978-981-15-9414-4_6
Vanessa Tran, J. Slavin
{"title":"Bone Tumour Pathology","authors":"Vanessa Tran, J. Slavin","doi":"10.1007/978-981-15-9414-4_6","DOIUrl":"https://doi.org/10.1007/978-981-15-9414-4_6","url":null,"abstract":"","PeriodicalId":21431,"journal":{"name":"Sarcoma","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2020-12-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44660941","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Assessment of Resection Margins in Bone Tumor Surgery. 骨肿瘤手术切除边缘的评估。
Q2 Medicine Pub Date : 2020-12-10 eCollection Date: 2020-01-01 DOI: 10.1155/2020/5289547
Corentin Malherbe, Bernard Crutzen, Jean Schrooyen, Giovanni Caruso, Frédéric Lecouvet, Christine Detrembleur, Thomas Schubert, Pierre-Louis Docquier

Limb salvage surgery is now the preferred procedure for bone tumor surgery. To decrease the risk of local recurrence, it is crucial to obtain adequate resection margins. The obtained margins must be evaluated postoperatively because they influence what treatment is given subsequently when margins are not adequate (e.g., surgical revision and radiotherapy). The study aims to evaluate margin assessment of tumor specimen by MRI compared to conventional histology (to establish the viability of using MRI) and assess the accuracy of a patient-specific instrument when narrow margins were aimed. The resection margins in 12 consecutive patients that were operated on for bone tumor resection were prospectively analyzed using three methods: MRI of the resection specimen, macroscopic evaluation of specimen slices, and microscopic pathological evaluation. The assessments were qualitative (R0, R1, and R2) and quantitative (distance in mm). MRI, macroscopic, and microscopic margins generated similar results for both the qualitative (all resections were R0) and quantitative assessments. The median error in safe margins was 2 mm with a surgical guide (PSI) and 5 mm without a surgical guide. Local recurrences were not detected after a mean follow-up period of 3.7 years (range, 2.1-5 years); however, four patients died during the study. In conclusion, MRI is a valuable tool for assessing safe margins. When specimens are not available for pathological assessment (e.g., extracorporeally irradiated autograft or autoclaved autograft), MRI could be used to evaluate margins. In particular, when tumor volume is high, MRI could also help to focus the pathological examination on areas of concern.

肢体保留手术现在是骨肿瘤手术的首选方法。为了降低局部复发的风险,获得足够的切除边缘是至关重要的。获得的切缘必须在术后进行评估,因为当切缘不充分时,它们会影响随后给予的治疗(例如手术修复和放疗)。本研究旨在评估MRI对肿瘤标本边缘的评估与传统组织学的比较(以确定使用MRI的可行性),并评估当目标是窄边缘时患者特异性仪器的准确性。对连续12例行骨肿瘤切除术的患者,采用切除标本MRI、标本切片宏观评价、显微病理评价三种方法对切除边缘进行前瞻性分析。定性评价(R0、R1和R2)和定量评价(以mm为单位的距离)。MRI、宏观和微观边缘在定性(所有切除均为R0)和定量评估中产生相似的结果。安全边缘的中位误差在有手术指南(PSI)时为2mm,没有手术指南时为5mm。平均随访3.7年(2.1-5年),未发现局部复发;然而,4名患者在研究期间死亡。总之,MRI是评估安全边界的一个有价值的工具。当标本无法用于病理评估时(例如,体外照射的自体移植物或高压灭菌的自体移植物),MRI可用于评估边缘。特别是当肿瘤体积较大时,MRI还可以帮助病理检查集中在关注的区域。
{"title":"Assessment of Resection Margins in Bone Tumor Surgery.","authors":"Corentin Malherbe,&nbsp;Bernard Crutzen,&nbsp;Jean Schrooyen,&nbsp;Giovanni Caruso,&nbsp;Frédéric Lecouvet,&nbsp;Christine Detrembleur,&nbsp;Thomas Schubert,&nbsp;Pierre-Louis Docquier","doi":"10.1155/2020/5289547","DOIUrl":"https://doi.org/10.1155/2020/5289547","url":null,"abstract":"<p><p>Limb salvage surgery is now the preferred procedure for bone tumor surgery. To decrease the risk of local recurrence, it is crucial to obtain adequate resection margins. The obtained margins must be evaluated postoperatively because they influence what treatment is given subsequently when margins are not adequate (e.g., surgical revision and radiotherapy). The study aims to evaluate margin assessment of tumor specimen by MRI compared to conventional histology (to establish the viability of using MRI) and assess the accuracy of a patient-specific instrument when narrow margins were aimed. The resection margins in 12 consecutive patients that were operated on for bone tumor resection were prospectively analyzed using three methods: MRI of the resection specimen, macroscopic evaluation of specimen slices, and microscopic pathological evaluation. The assessments were qualitative (R0, R1, and R2) and quantitative (distance in mm). MRI, macroscopic, and microscopic margins generated similar results for both the qualitative (all resections were R0) and quantitative assessments. The median error in safe margins was 2 mm with a surgical guide (PSI) and 5 mm without a surgical guide. Local recurrences were not detected after a mean follow-up period of 3.7 years (range, 2.1-5 years); however, four patients died during the study. In conclusion, MRI is a valuable tool for assessing safe margins. When specimens are not available for pathological assessment (e.g., extracorporeally irradiated autograft or autoclaved autograft), MRI could be used to evaluate margins. In particular, when tumor volume is high, MRI could also help to focus the pathological examination on areas of concern.</p>","PeriodicalId":21431,"journal":{"name":"Sarcoma","volume":"2020 ","pages":"5289547"},"PeriodicalIF":0.0,"publicationDate":"2020-12-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2020/5289547","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38854962","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Biopsy 活组织检查
Q2 Medicine Pub Date : 2020-12-10 DOI: 10.1007/978-981-15-9414-4_5
Peter F. M. Choong
{"title":"Biopsy","authors":"Peter F. M. Choong","doi":"10.1007/978-981-15-9414-4_5","DOIUrl":"https://doi.org/10.1007/978-981-15-9414-4_5","url":null,"abstract":"","PeriodicalId":21431,"journal":{"name":"Sarcoma","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2020-12-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"51108875","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Sarcoma
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1